Skip to main content

Hester Biosciences Limited (HESTERBIO.NS)

National Stock Exchange of India Healthcare Drug Manufacturers - Specialty & GenericView data quality →
47.6Fair

ValueMarkers Composite Index

Top 22%#34,740 of 44,714

DCF data not available

Piotroski
8/9
Strong
Beneish
-3.08
Low Risk
Altman
3.61
Safe
DCF Value
-
N/A
ROIC
6.9%
Low
P/E
30.1
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Hester Biosciences Limited (HESTERBIO.NS) — VMCI valuation read

Hester Biosciences Limited sits at VMCI 48/100, with the Healthcare sector median at 50. That 2-point spread is the first thing to note on HESTERBIO.NS: it tells the reader the composite is unfavorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on HESTERBIO.NS are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on HESTERBIO.NS: HESTERBIO.NS trades at 18.0x earnings, 0% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 16.0% sits 6.0pp above the Healthcare median (10.0%). The Risk read: net debt to EBITDA of 0.6x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.

HESTERBIO.NS rose 1.1% over the trailing 7 days, with a -1.3% read on a 30-day basis.

Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates in two segments, Poultry Healthcare and Animal Healthcare. The company provides poultry vaccines for diseases, such as newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, egg drop syndrome, reo, marek's disease, infectious coryza, fowl cholera, mycoplasma gallisepticum, inclusion body hepatitis, avian encephalomyelitis, etc. It also offers vaccines for large animals comprising Goat Pox, Peste des Petits Ruminants, Brucellosis, Mastitis, Metritis, and various infectious diseases, as well as infections, reproductive disorders, theileriosis, parasitic diseases, etc. In addition, the company provides feed supplements, such as toxin binder, trace minerals, enzyme preparation, and bypass fat; disinfectants for farms and equipment, and water sanitizers; nutrition products consisting of mineral mixtures, fertility supplements, and growth tonics; and herbal products, including growth promoters, herbal replacers for choline chloride, stress relievers and immunity boosters, respiratory stimulants, liver tonics, wound healing preparations, uterine tonics, digestive tonics and anti-bloat solutions, ectoparasiticide preparations, anti-mastitis, and anti-prolapse preparations. Hester Biosciences Limited was incorporated in 1987 and is headquartered in Ahmedabad, India.

CEO: Rajiv Dinesh Gandhi642 employeesINwww.hester.in

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in HESTERBIO.NS’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.